Esketamine in Depression: Real-World Outcomes vs. Clinical Trials

Real-World Esketamine Outcomes Appear Stronger Than Clinical Trial Results

Recent narrative review research published in November 2026 (OpenAlex W7225178527) highlights a notable discrepancy: patients with treatment-resistant depression (TRD) receiving intranasal esketamine in real-world clinical practice report greater symptom reductions and higher remission rates than those observed in randomized controlled trials (RCTs). This finding is significant for clinicians, payers, and policymakers tasked with evaluating esketamine's clinical and economic value.

Esketamine, approved by the U.S. Food and Drug Administration (FDA) in 2019 for TRD, was initially authorized based on RCTs demonstrating modest efficacy compared to active controls. However, observational studies and registry data from routine care settings since then have suggested more substantial benefits, creating a paradox that demands careful interpretation.

Mechanisms Behind the Discrepancy: Methodological and Clinical Factors

The primary reason real-world outcomes for esketamine appear more favorable than trial results is methodological, not pharmacological. RCTs for esketamine typically included an active comparator—patients in both arms received a new oral antidepressant in addition to either esketamine or placebo. This design, while ethically sound, narrows the observed difference between groups. Furthermore, placebo response rates in ketamine and esketamine studies are notably high, further diluting the apparent effect size.

In contrast, real-world studies often lack a control group and are subject to several factors that can artificially inflate perceived effectiveness:

• Therapeutic Expectation: Patients and clinicians aware of receiving an innovative treatment may report greater improvement due to expectation effects.
• Patient Selection: Clinical practice may include individuals excluded from trials, such as those with comorbidities or prior treatment failures, whose outcomes may differ.
• Dose Flexibility: Real-world dosing is often adjusted based on response and tolerability, unlike fixed protocols in trials.
• Loss to Follow-Up: Patients who do not benefit may discontinue treatment and be underrepresented in outcome reporting.

Importantly, while these factors can exaggerate effectiveness, real-world settings also provide insights into functional gains and benefits among populations not represented in trials, such as older adults or those with complex psychiatric histories.

Policy, Research, and Clinical Implications

For decision-makers, the divergence between real-world and trial outcomes underscores the importance of integrating evidence from both sources. Policymakers and payers should be cautious in interpreting observational data as proof of superior efficacy, recognizing that methodological biases can overstate benefits. The review recommends ongoing outcome monitoring, investment in pragmatic controlled studies, and the development of registries to capture both clinical and functional endpoints.

For researchers, the findings highlight the need for study designs that bridge the gap between RCT rigor and real-world applicability. Hybrid or pragmatic trials—combining randomization with routine care conditions—may offer a path forward. Additionally, harmonizing outcome measures across studies can facilitate more meaningful comparisons and meta-analyses.

One non-obvious implication is that real-world data may reveal subgroups who derive disproportionate benefit or experience unique risks, guiding personalized approaches and future trial stratification. For example, registry data could identify predictors of sustained remission or adverse effects in populations previously excluded from trials.

Risks, Limitations, and Unknowns

The apparent superiority of real-world esketamine outcomes does not equate to greater intrinsic efficacy. Risks of overestimating effectiveness include inappropriate expansion of indications, reimbursement decisions not grounded in robust evidence, and potential under-recognition of adverse effects. Real-world studies are also vulnerable to reporting bias and incomplete follow-up, which can mask both failures and harms.

Clinical trials, while limited in generalizability, remain the gold standard for establishing causality. However, their restrictive inclusion criteria may omit patients most likely to be seen in practice. Balancing these limitations requires critical integration of both data streams, as well as transparency about uncertainties and ongoing surveillance for long-term safety and effectiveness.

Looking Ahead: Integrating Evidence for Rational Esketamine Use

Future progress in esketamine research and policy will depend on harmonizing the strengths of both controlled trials and real-world evidence. The review calls for comparative effectiveness studies, standardized outcome tracking, and adaptive trial designs that reflect clinical realities. For clinicians, a nuanced understanding of both the promise and limitations of current evidence is essential for informed patient care and shared decision-making.

As esketamine use expands, stakeholders must remain vigilant about distinguishing true therapeutic advances from artifacts of study design. Ongoing research, transparent reporting, and collaborative registries will be crucial to optimizing the safe, effective, and equitable use of esketamine for treatment-resistant depression.

How we research: This article was written and reviewed by Dr. Alex M. Hart, PhD (neuroscience and policy editor), on 2026-11-04. All primary sources are cited directly, including the OpenAlex review (W7225178527) and FDA approval documents.